Go Pro
OTCMKTS:EKTAY

Elekta Q3 2026 Earnings Report

Elekta logo
$5.09 0.00 (0.00%)
As of 09/25/2026 01:10 PM Eastern

Elekta EPS Results

Actual EPS
$0.09
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Elekta Revenue Results

Actual Revenue
$433.29 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Elekta Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Elekta's next earnings date is estimated for Wednesday, November 25, 2026, based on past reporting schedules.

Conference Call Resources

Elekta Earnings Headlines

Insulet (NASDAQ:PODD) & Elekta (OTCMKTS:EKTAY) Critical Comparison
First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
Elekta AB earnings call: margins up, growth uneven
Elekta AB (publ) (EKTAY) Q1 2027 Earnings Call Transcript
See More Elekta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elekta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elekta and other key companies, straight to your email.

About Elekta

Elekta (OTCMKTS:EKTAY) is a Sweden-based medical technology company focused on radiation oncology and precision treatment solutions. The company develops and supplies systems used to diagnose, plan and deliver treatments for cancer and other conditions affecting the brain and nervous system.

Its product portfolio includes linear accelerators for external-beam radiotherapy, stereotactic radiosurgery systems such as Leksell Gamma Knife, brachytherapy equipment and treatment-planning, oncology information and workflow software. Elekta also provides related services, support and upgrades for healthcare providers.

Founded in 1972 by neurosurgeon Lars Leksell, Elekta has grown into an international supplier serving hospitals, clinics and cancer centers across Europe, North and South America, Asia-Pacific, the Middle East and Africa. The company is headquartered in Stockholm, Sweden, and its shares trade on Nasdaq Stockholm under the symbol “EKTA”; its American depositary shares trade over the counter under the symbol “EKTAY.”

View Elekta Profile